ReviewPathogens (Basel, Switzerland)2016
How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions.
Review in Pathogens (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Pooled it
- Hac1-independent functions of Ire1 drive morphogenesis in Candida albicans through distinct transcriptional programs.Journal of cell science · 2026Article
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- Modeling Gut Barrier Dysfunction and Subsequent Opportunistic Infection by Candida albicans During Chemotherapy-Induced Intestinal Mucositis in Mice.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Systemic Antifolate Chemotherapy Does Not Select for Fluconazole-ResistantPathogens (Basel, Switzerland) · 2025Article
- Antifungal Resistance Among Candida Species: Diagnostic and Clinical Challenges in Specialized Cancer Care Hospital of Lahore.Journal of clinical laboratory analysis · 2025Article
- Neutrophil extracellular traps capture the human pathogen, Candida albicans, in blood and delay hyphal transformation.Journal of leukocyte biology · 2025Article
- Kefir probiotic products on the count of Candida Albicans in saliva of chemotherapy patients: A randomized placebo-controlled single-blind study.Caspian journal of internal medicine · 2025Article
- Evaluation of epidemiological, clinical, and microbiological features of vulvovaginal candidiasis.GMS hygiene and infection control · 2025Article
- Global Epidemiology of Invasive Infections by UncommonJournal of fungi (Basel, Switzerland) · 2024Review
- Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- A machine learning model for early candidemia prediction in the intensive care unit: Clinical application.PloS one · 2024Article
- Article
- Antimicrobial Effects of Plant-Based Supplements on Gut Microbial Diversity in Small Ruminants.Pathogens (Basel, Switzerland) · 2023Review
- Muscular and hepatosplenic candidiasis in a patient with acute myeloblastic leukemia: A case report and literature review.Clinical case reports · 2023Article
- A Putative Role ofMicroorganisms · 2023Review
- Non-self glycan structures as possible modulators of cancer progression: would polysaccharides from Cryptococcus spp. impact this phenomenon?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Infections of Tumor Prostheses: An Updated Review on Risk Factors, Microbiology, Diagnosis, and Treatment Strategies.Biology · 2023Review
- Stress combined with loss of the Candida albicans SUMO protease Ulp2 triggers selection of aneuploidy via a two-step process.PLoS genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is a fungal commensal and a major colonizer of the human skin, as well as of the gastrointestinal and genitourinary tracts. It is also one of the leading causes of opportunistic microbial infections in cancer patients, often presenting in a life-threatening, systemic form. Increased susceptibility to such infections in cancer patients is attributed primarily to chemotherapy-induced depression of innate immune cells and weakened epithelial barriers, which are the body's first-line defenses against fungal infections. Moreover, classical chemotherapeutic agents also have a detrimental effect on components of the adaptive immune system, which further play important roles in the antifungal response. In this review, we discuss the current paradigm regarding the mechanisms behind the increased risk of systemic candidiasis in cancer patients. We also highlight some recent findings, which suggest that chemotherapy may have more extensive effects beyond the human host, in particular towards C. albicans itself and the bacterial microbiota. The extent to which these additional effects contribute towards the development of candidiasis in chemotherapy-treated patients remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.